TRT week 9 euphoria: what the science says about early results

What did @codyontrt actually say?

At week nine of testosterone replacement therapy, Cody reported a sweeping improvement across nearly every dimension of his life. "The energy is off the charts," he said, adding that his libido, gym performance, confidence, mood, and motivation had all improved dramatically. Most notably, he said he "can't tell you the last time I've had a bad day" and reported zero negatives from TRT so far. This is a glowing, essentially unqualified endorsement of TRT at the two-month mark.

To be fair, Cody is describing his own subjective experience, not making clinical claims for other people. He never says TRT will work the same way for everyone. But the framing, no negatives, everything better, can't imagine going back, is the kind of testimony that can push someone with borderline-normal testosterone toward seeking a prescription they may not need.

Does the science back this up?

Partially, yes. The symptom improvements Cody describes are well-documented in men with confirmed hypogonadism. But the timeline and the completeness of his response raise some questions worth examining.

Energy and mood improvements in hypogonadal men on TRT are real and well-supported. A 2011 meta-analysis by Isidori et al. in the European Journal of Endocrinology found significant improvements in fatigue, mood, and quality of life in men with low testosterone on replacement therapy. Libido improvements are also among the most consistently reported benefits. A 2016 randomized controlled trial, the Testosterone Trials (TTrials), published in the New England Journal of Medicine by Snyder et al., found that testosterone treatment improved sexual function and libido in older men with confirmed hypogonadism.

However, the TTrials also showed that mood and energy benefits were more modest and variable than many TRT advocates suggest. The idea that TRT produces a universally euphoric, problem-free experience at nine weeks is not what controlled trials typically show. Many participants experience a more nuanced response.

What did they get wrong (or right)?

Cody got the general trajectory right for someone who genuinely had low testosterone. If his levels were clinically low before starting, the improvements he describes, better mood, energy, libido, gym output, are biologically plausible and consistent with the literature.

What he got wrong, or at least incomplete, is the "I don't have any negatives to talk about" part. That is where this video becomes genuinely misleading for a general audience. TRT carries real risks that tend to emerge over time, not at week nine. Erythrocytosis (elevated hematocrit) is one of the most common adverse effects, affecting up to 25 percent of men on injectable testosterone according to a 2017 review by Bachman et al. in Current Opinion in Endocrinology, Diabetes and Obesity. Testicular atrophy and suppression of natural testosterone production through the hypothalamic-pituitary-gonadal axis also begin within weeks of starting TRT. These are not rare edge cases. They are expected physiological consequences that require monitoring.

Framing nine weeks as a complete picture, with no downsides worth mentioning, leaves out the part of the story that his audience most needs to hear before deciding whether to pursue TRT themselves.

What should you actually know?

TRT is a legitimate medical treatment for confirmed hypogonadism, and the benefits Cody describes are real for the right candidate. But "feeling amazing at week nine" is not a substitute for a proper diagnostic workup, including at minimum two morning total testosterone measurements, LH, FSH, and a discussion of your baseline hematocrit and fertility plans.

The risks of TRT that do not show up in feel-good week nine videos include:

• Erythrocytosis, which increases cardiovascular risk and requires regular blood monitoring
• Infertility due to suppression of sperm production, which can be partially irreversible
• Testicular atrophy from HPG axis suppression
• Potential cardiovascular effects that remain under active study
• Dependence on exogenous testosterone once natural production is suppressed

A 2023 large-scale RCT, the TRAVERSE trial by Lincoff et al. in the New England Journal of Medicine, provided some reassurance on cardiovascular safety in men with hypogonadism and existing cardiovascular risk factors, but it was not a blanket safety clearance for all TRT use. Healthy 30-year-olds seeking "optimization" were not the study population.

If you are considering TRT after watching videos like this one, the right first step is bloodwork and a conversation with an endocrinologist or urologist, not a telehealth prescription based on a symptom checklist alone.